New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
07:48 EDTLCILannett price target raised to $9 from $6 at Oppenheimer
Oppenheimer increased its price target on Lannett after the company reported higher than expected Q2 EPS. The firm notes that the company may be first-to-file for approval of thalidomide, now believed to represent a generic opportunity of 200M, and it maintains an Outperform rating on the shares.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
12:23 EDTLCIOn The Fly: Top stock stories at midday
Subscribe for More Information
09:04 EDTLCILannett acquisition positive, says Roth Capital
After Lannett (LCI) agreed to buy Kremers Urban Pharmaceuticals, Roth Capital says that the deal could potentially double Lannett's revenue base and lift its EPS by 20%-25% in 2017. The firm says that Kremers could surpass Lannett's guidance if the FDA switches its rating on Kremer's Methylphenidate drug to AB from BX. The firm notes that the agency is considering such a change. Roth raised its price target on the name to $68 from $64 and reiterates a Buy rating.
07:50 EDTLCILannett acquisition provides 'much needed jolt,' says Oppenheimer
Subscribe for More Information
September 2, 2015
18:39 EDTLCIOn The Fly: After Hours Movers
UP AFTER EARNINGS: SeaChange (SEAC), up 4.5%... Planet Fitness (PLNT), up 7.1%. ALSO HIGHER: Geron (GERN), up 19.7% after publishing two papers in The New England Journal of Medicine... Lannett (LCI), up 16.6% after announcing that it will acquire Kremers Urban. DOWN AFTER EARNINGS: Five Below (FIVE), down 9.3%... Verint Systems (VRNT), down 6.1%... Catalent (CTLT), down 4.9%.
16:36 EDTLCILannett up 9.1% after announcing that it will acquire Kremers Urban
16:35 EDTLCILannett to acquire Kremers Urban Pharmaceuticals For $1.23B
Subscribe for More Information
16:34 EDTLCILannett to acquire Kremers Urban Pharmaceuticals For $1.23B
August 26, 2015
08:44 EDTLCILannett steady execution offers compelling upside, says Susquehanna
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
August 25, 2015
16:08 EDTLCILannett sees FY16 CapEx $60M-$70M
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
16:06 EDTLCILannett sees FY16 revenue $425M-$435M, consensus $433.55M
16:05 EDTLCILannett reports Q4 EPS 91c, consensus 86c
Reports Q4 revenue $99.3M, consensus $97.62M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use